AMP is the consulting practice that help start-ups and established medtech, biotech and pharmaceutical companies with limited market access and business development capacity. We help you develop and execute systematic strategies that integrate health economics, outcomes research and market access solutions across all stages of the product life cycle, and to expand company portfolios and the international reach, to ensure a competitive advantage and commercial success.

• Led and executed licensing deal with Jiangsu Hengrui for global rights (EX-China and Korea) of Camrelizumab, a PD-1, for use in combination with Elevar’s TKI, Rivoceranib. Deal value of $600M, with double digit royalty and opportunities for a total deal value of $1 Billion.• Led all alliances, including the Hengrui alliance to file the Camrelizumab BLA and Rivoceranib NDA with FDA for 1L unresected hepatocellular carcinoma.• Created and led the global licensing and search & evaluation process, managing a cross functional diligence team to identify, evaluate and execute new business opportunities, including market research, deal valuation, diligence, negotiation, and deal closure.• Led cross-functional team (medical, marketing, market access/reimbursement, regulatory, CMC, quality, legal) to create and manage development of the corporate deck, and led discussions with potential partners, presenting business and scientific content, leading to CDAs and further diligence.

• Led governance committees for partnerships of Apealea and Rivoceranib (China, Europe/Russia, MENA, Global Compassionate Use Program), managing stakeholder expectations, risks, and business issues. • Managed complex co-development alliance for a combination product in hepatocellular carcinoma targeted for the global market.• Managed contract compliance with Legal, Finance, CMC, Quality, Safety, Regulatory, Medical. • Supported Business Development and cross functional diligence team in the review of agreements for licensing opportunities. • Prepared and implemented Alliance Management Best Practices, Governance Model Template, and Alliance software, enhancing collaboration and data sharing with partners.

P• Oversee EX-US business (India, Japan, MENA, Global Named Patient Global, Europe, Latin America, Canada, Switzerland), and internal program activities for Acrotech’s commercial products (Zevalin, Marqibo, Evomela, Beleodaq, Folotyn, Khapzory).• Oversaw eight (8) alliance partnerships accounting for >15% of corporate revenue. • Led governance committees, managing stakeholder expectations, risks, and business issues. • Supported brand teams to prepare annual strategic goals leading to actionable tactics to complete, and monitored cross-functional activities for all products with input from Marketing, Commercial, R&D, Medical, Regulatory, Finance, Legal, and IP.• Supported the integration of the acquired products into the parent organization, including transfer of core processes, NDAs, INDs, DMFs, a BLA clinical operations activities to the supporting CRO, and marketing authorization holdership for Zevalin in Europe. • Supported Business Development and due diligence team for new deals and partnerships, with a focus on operational aspects to ensure feasibility of execution.

• Chaired development and strategy committees for Spectrum’s commercial brands; Zevalin, Marqibo, Evomela, Beleodaq, Folotyn, Fusilev, and Khapzory.• Led teams to establish program annual strategic goals, life cycle and operational plans across all functions (Marketing, Commercial, CMC/Supply, Clinical, QA/QC, Regulatory).• Created annual strategy planning process, focusing on aligning Commercial, Medical, Marketing andR&D activities with corporate goals. • Created process for implementation of corporate Expanded Access Program• Managed alliance partnerships, leading to five (5) country approvals for Folotyn and Zevalin, and approval of Evomela in China.• Co-led Evomela launch team, launching the product w/in 45 days of PDUFA. Gained more than 50% market share in the first year.• Led team to develop business case and gain approval for a new therapeutic space.• Led governance committees, managing stakeholder expectations, risks, and business issues. • Supported Business Development in due diligence team for review of agreements (License, Quality, Pharmacovigilance, Supply Chain), focusing on operational activities for execution.

• Managed more than 15 US and Global projects, generating more than $60M in revenue.• Led cross functional teams (CMC, Commercial, Regulatory, Quality) resulting in two product approvals, Viread oral power and Propranolol LA Capsules. • Chaired Customer Oversight Committee and Supported Product Strategy Group, collaborating with key internal and external stakeholders to decide on which projects to pursue.• Co-created best practices for Alliance Management and Project Management.• Developed a Global Pharmaceutical Development Process best practice across three R&D sites.

• Acted as the Scientific lead for the formulation development of internal and customer ANDA and NDA projects.• Finalized R&D activities and sNDA preparations for approval of Lamictal ODT.